1. Clinical & Scientific Overview
Entecavir (TIP-MED-000348, Reference Code [8.36]-C78) is classified under
Antimicrobials — Antiviral & Antiretroviral Agents (Ch 08) as a Nucleotide/Nucleoside Reverse Transcriptase Inhibitors & Integrase Strand Transfer Inhibitor — NACO / NVHCP Antivirals (Schedule H | NLEM 2022).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Co-indexed constituent under primary monograph [8.36] (Tenofovir Disoproxil Fumarate (TDF), Entecavir & Dolutegravir-Based ART (TLD)). Representative Indian Market Examples (Edition 2.7 Ch 08 [8.36], p. 110): Tenofovir (TDF): Tenvir (Cipla), Ricovir (Mylan); Tenofovir Alafenamide (TAF 25 mg): Tafnat, HepBest. Entecavir: Entavir (Cipla), Baraclude. TLD Fixed-Dose Combination: Tenofovir 300 mg + Lamivudine 300 mg + Dolutegravir 50 mg (Tenvir-LD, Acriptega) — Strengths & Dosage Forms: TDF Tablets: 300 mg. Entecavir Tablets: 0.5 mg, 1 mg. Dolutegravir (DTG) Tablets: 50 mg. TLD Single-Tablet Regimen: 300/300/50 mg
TDF Tablets: 300 mg. Entecavir Tablets: 0.5 mg, 1 mg. Dolutegravir (DTG) Tablets: 50 mg. TLD Single-Tablet Regimen: 300/300/50 mg
3. Mechanism of Action & Pharmacodynamics
Nucleotide/Nucleoside Reverse Transcriptase Inhibitors & Integrase Strand Transfer Inhibitor — NACO / NVHCP Antivirals (Schedule H | NLEM 2022) acting on target receptor/enzyme pathways in Antimicrobials — Antiviral & Antiretroviral Agents (Ch 08): clinical efficacy is mediated via Nucleotide/Nucleoside Reverse Transcriptase Inhibitors & Integrase Strand Transfer Inhibitor — NACO / NVHCP Antivirals (Schedule H | NLEM 2022) for Chronic Hepatitis B Virus (HBV) infection (Entecavir 0.5 mg OD or TDF 300 mg OD / TAF 25 mg OD under NVHCP); First-line HIV-1 & HIV-2 Antiretroviral Therapy and Post-Exposure Prophylaxis (PEP x 28 days) using TLD (under NACO guidelines).
4. Therapeutic Indications & Evidence-Supported Uses
- Chronic Hepatitis B Virus (HBV) infection (Entecavir 0
- 5 mg OD or TDF 300 mg OD / TAF 25 mg OD under NVHCP)
- First-line HIV-1 & HIV-2 Antiretroviral Therapy and Post-Exposure Prophylaxis (PEP x 28 days) using TLD (under NACO guidelines)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Chronic HBV: Entecavir 0.5 mg PO OD (1 mg OD if decompensated cirrhosis) OR TDF 300 mg PO OD (or TAF 25 mg OD if eGFR <60 or osteoporosis). HIV-1/2 (First-Line NACO & 28-Day PEP): 1 TLD tablet (300/300/50 mg) PO Once Daily
Administration & Meal Timing: Entecavir MUST be taken on an EMPTY STOMACH (at least 2h before or 2h after a meal!). TDF and TLD may be taken with or without food. CRITICAL CHELATION RULE: Separate Dolutegravir (TLD) by >=2 hours BEFORE or >=6 hours AFTER Calcium, Iron, Mg/Al Antacids, or Multivitamins! | Entecavir: Bedtime (2h after dinner on empty stomach). TLD / TDF: Morning (Once Daily)
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Follows class pharmacokinetic profile detailed in parent monograph [8.36].
Renal: TDF 300 mg: Adjust interval if CrCl <50 mL/min (avoid TLD fixed-dose tablet if CrCl <50 mL/min; switch TDF to Abacavir or TAF!). Entecavir: 0.5 mg q48h (CrCl 30–49), q72h (CrCl 10–29), or q7d post-HD
Renal: TDF 300 mg: Adjust interval if CrCl <50 mL/min (avoid TLD fixed-dose tablet if CrCl <50 mL/min; switch TDF to Abacavir or TAF!). Entecavir: 0.5 mg q48h (CrCl 30–49), q72h (CrCl 10–29), or q7d post-HD
Renal: TDF 300 mg: Adjust interval if CrCl <50 mL/min (avoid TLD fixed-dose tablet if CrCl <50 mL/min; switch TDF to Abacavir or TAF!). Entecavir: 0.5 mg q48h (CrCl 30–49), q72h (CrCl 10–29), or q7d post-HD
7. Contraindications, Precautions & High-Risk Warnings
- BOXED WARNING — SEVERE ACUTE EXACERBATION OF HEPATITIS B ON DISCONTINUATION: Never abruptly stop TDF, TAF, Entecavir, or Lamivudine (TLD) in any patient with Chronic Hepatitis B (causes fatal fulminant HBV flare!). Test HBV patients for HIV before starting Entecavir monotherapy!
Key Clinical Precautions: Renal: TDF 300 mg: Adjust interval if CrCl <50 mL/min (avoid TLD fixed-dose tablet if CrCl <50 mL/min; switch TDF to Abacavir or TAF!). Entecavir: 0.5 mg q48h (CrCl 30–49), q72h (CrCl 10–29), or q7d post-HD
8. Adverse Effects Profile
- TDF: Proximal renal tubular dysfunction, bone mineral density loss, mild nausea. Dolutegravir: Insomnia, headache, weight gain (3–5 kg), reversible 0.1–0.2 mg/dL rise in serum creatinine (OCT2 tubular inhibition without true GFR reduction!)
- TDF-induced Fanconi Syndrome (hypophosphataemia, renal glycosuria, proteinuria, osteomalacia, AKI — switch to TAF 25 mg or Entecavir!), lactic acidosis with severe hepatomegaly/steatosis, IRIS
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- CRITICAL DOLUTEGRAVIR (TLD) INTERACTIONS: (1) Rifampicin cuts Dolutegravir levels by 54% -> MUST give an extra Dolutegravir 50 mg tablet 12 hours after TLD (so DTG is 50 mg TWICE DAILY) throughout Rifampicin therapy!; (2) Dolutegravir inhibits renal OCT2 -> DOUBLES Metformin plasma levels (cap Metformin at max 1000 mg/day [500 mg BD]!); (3) Cationic supplements (Ca, Fe, Mg, Zn, Antacids) chelate Dolutegravir and cause HIV failure (separate 2h before / 6h after!)
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical parameters per parent monograph [8.36].
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: FOUR CRITICAL COUNTER RULES: (1) Take Entecavir (Entavir) on a strict empty stomach 2 hours after dinner; (2) If taking TLD for HIV, space Iron, Calcium, or Antacids at least 2 hours after (or 6 hours before) TLD; (3) If a patient on TLD starts Rifampicin for TB, ensure an extra evening Dolutegravir 50 mg tablet is added; (4) If diabetic on TLD + Metformin, cap Metformin at max 1000 mg/day
- Meal & Clock Timing Instruction: Entecavir MUST be taken on an EMPTY STOMACH (at least 2h before or 2h after a meal!). TDF and TLD may be taken with or without food. CRITICAL CHELATION RULE: Separate Dolutegravir (TLD) by >=2 hours BEFORE or >=6 hours AFTER Calcium, Iron, Mg/Al Antacids, or Multivitamins! (Entecavir: Bedtime (2h after dinner on empty stomach). TLD / TDF: Morning (Once Daily))
- Missed Dose Protocol: Take same day as soon as remembered; NEVER run out of stock (stopping causes viral rebound & fatal HBV flare)
- Geriatric Dispensing Pearl: In older adults or patients with eGFR <60 mL/min or osteoporosis, prefer TAF 25 mg or Entecavir over TDF 300 mg
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: TDF Tablets: 300 mg. Entecavir Tablets: 0.5 mg, 1 mg. Dolutegravir (DTG) Tablets: 50 mg. TLD Single-Tablet Regimen: 300/300/50 mg
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [8.14]-CMP56 Valacyclovir Hydrochloride IP — Synthetic Purine Nucleoside Analogue Antiviral (Activated by Vira
- [8.36]-C79 Tenofovir + Lamivudine + Dolutegravir (TLD ART FDC) — Nucleotide/Nucleoside Reverse Transcriptase Inhibitors & Integras
- [8.14] Acyclovir (Aciclovir) (and Valacyclovir comparison) — Synthetic Purine Nucleoside Analogue Antiviral (Activated by Vira
- [8.35] Oseltamivir Phosphate — Influenza A & B Viral Neuraminidase Inhibitor (Schedule H1 | NLEM